Literature DB >> 24928044

Diversity of the murine antibody response targeting influenza A(H1N1pdm09) hemagglutinin.

Jason R Wilson1, Wen-Pin Tzeng1, April Spesock1, Nedzad Music1, Zhu Guo1, Robert Barrington2, James Stevens1, Ruben O Donis1, Jacqueline M Katz1, Ian A York3.   

Abstract

UNLABELLED: We infected mice with the 2009 influenza A pandemic virus (H1N1pdm09), boosted with an inactivated vaccine, and cloned immunoglobulins (Igs) from HA-specific B cells. Based on the redundancy in germline gene utilization, we inferred that between 72-130 unique IgH VDJ and 35 different IgL VJ combinations comprised the anti-HA recall response. The IgH VH1 and IgL VK14 variable gene families were employed most frequently. A representative panel of antibodies were cloned and expressed to confirm reactivity with H1N1pdm09 HA. The majority of the recombinant antibodies were of high avidity and capable of inhibiting H1N1pdm09 hemagglutination. Three of these antibodies were subtype-specific cross-reactive, binding to the HA of A/South Carolina/1/1918(H1N1), and one further reacted with A/swine/Iowa/15/1930(H1N1). These results help to define the genetic diversity of the influenza anti-HA antibody repertoire profile induced following infection and vaccination, which may facilitate the development of influenza vaccines that are more protective and broadly neutralizing. IMPORTANCE: Protection against influenza viruses is mediated mainly by antibodies, and in most cases this antibody response is narrow, only providing protection against closely related viruses. In spite of this limited range of protection, recent findings indicate that individuals immune to one influenza virus may contain antibodies (generally a minority of the overall response) that are more broadly reactive. These findings have raised the possibility that influenza vaccines could induce a more broadly protective response, reducing the need for frequent vaccine strain changes. However, interpretation of these observations is hampered by the lack of quantitative characterization of the antibody repertoire. In this study, we used single-cell cloning of influenza HA-specific B cells to assess the diversity and nature of the antibody response to influenza hemagglutinin in mice. Our findings help to put bounds on the diversity of the anti-hemagglutinin antibody response, as well as characterizing the cross-reactivity, affinity, and molecular nature of the antibody response.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Affinity; Antibody; Cloning; Germline; Influenza; Repertoire

Mesh:

Substances:

Year:  2014        PMID: 24928044      PMCID: PMC4904151          DOI: 10.1016/j.virol.2014.04.011

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  47 in total

1.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

Review 2.  T cell receptor biochemistry, repertoire selection and general features of TCR and Ig structure.

Authors:  M M Davis; D S Lyons; J D Altman; M McHeyzer-Williams; J Hampl; J J Boniface; Y Chien
Journal:  Ciba Found Symp       Date:  1997

3.  Receptor specificity of subtype H1 influenza A viruses isolated from swine and humans in the United States.

Authors:  Li-Mei Chen; Pierre Rivailler; Jaber Hossain; Paul Carney; Amanda Balish; Ijeoma Perry; C Todd Davis; Rebecca Garten; Bo Shu; Xiyan Xu; Alexander Klimov; James C Paulson; Nancy J Cox; Sabrina Swenson; James Stevens; Amy Vincent; Marie Gramer; Ruben O Donis
Journal:  Virology       Date:  2011-02-18       Impact factor: 3.616

4.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

5.  Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

Authors:  Surender Khurana; Crystal L Loving; Jody Manischewitz; Lisa R King; Phillip C Gauger; Jamie Henningson; Amy L Vincent; Hana Golding
Journal:  Sci Transl Med       Date:  2013-08-28       Impact factor: 17.956

6.  Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.

Authors:  Jens Wrammert; Dimitrios Koutsonanos; Gui-Mei Li; Srilatha Edupuganti; Jianhua Sui; Michael Morrissey; Megan McCausland; Ioanna Skountzou; Mady Hornig; W Ian Lipkin; Aneesh Mehta; Behzad Razavi; Carlos Del Rio; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Zahida Ali; Kaval Kaur; Sarah Andrews; Rama Rao Amara; Youliang Wang; Suman Ranjan Das; Christopher David O'Donnell; Jon W Yewdell; Kanta Subbarao; Wayne A Marasco; Mark J Mulligan; Richard Compans; Rafi Ahmed; Patrick C Wilson
Journal:  J Exp Med       Date:  2011-01-10       Impact factor: 14.307

7.  The receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies.

Authors:  P S Daniels; S Jeffries; P Yates; G C Schild; G N Rogers; J C Paulson; S A Wharton; A R Douglas; J J Skehel; D C Wiley
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

8.  Modulation of immunodominant sites in influenza hemagglutinin compromise antigenic variation and select receptor-binding variant viruses.

Authors:  F Temoltzin-Palacios; D B Thomas
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

9.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.

Authors:  Jianhua Sui; William C Hwang; Sandra Perez; Ge Wei; Daniel Aird; Li-mei Chen; Eugenio Santelli; Boguslaw Stec; Greg Cadwell; Maryam Ali; Hongquan Wan; Akikazu Murakami; Anuradha Yammanuru; Thomas Han; Nancy J Cox; Laurie A Bankston; Ruben O Donis; Robert C Liddington; Wayne A Marasco
Journal:  Nat Struct Mol Biol       Date:  2009-02-22       Impact factor: 15.369

10.  Complete sequence assembly and characterization of the C57BL/6 mouse Ig heavy chain V region.

Authors:  Colette M Johnston; Andrew L Wood; Daniel J Bolland; Anne E Corcoran
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

View more
  5 in total

1.  Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus.

Authors:  Jason R Wilson; Zhu Guo; Wen-Pin Tzeng; Rebecca J Garten; Xu Xiyan; Elisabeth G Blanchard; Kristy Blanchfield; James Stevens; Jacqueline M Katz; Ian A York
Journal:  Virology       Date:  2015-08-27       Impact factor: 3.616

Review 2.  Biosensor-based epitope mapping of antibodies targeting the hemagglutinin and neuraminidase of influenza A virus.

Authors:  Zhu Guo; Jason R Wilson; Ian A York; James Stevens
Journal:  J Immunol Methods       Date:  2018-07-24       Impact factor: 2.303

3.  An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge.

Authors:  Jason R Wilson; Jessica A Belser; Juliana DaSilva; Zhu Guo; Xiangjie Sun; Shane Gansebom; Yaohui Bai; Thomas J Stark; Jessie Chang; Paul Carney; Min Z Levine; John Barnes; James Stevens; Taronna R Maines; Terrence M Tumpey; Ian A York
Journal:  Virology       Date:  2017-09-06       Impact factor: 3.616

4.  An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.

Authors:  Jason R Wilson; Zhu Guo; Adrian Reber; Ram P Kamal; Nedzad Music; Shane Gansebom; Yaohui Bai; Min Levine; Paul Carney; Wen-Pin Tzeng; James Stevens; Ian A York
Journal:  Antiviral Res       Date:  2016-10-03       Impact factor: 5.970

5.  Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics.

Authors:  Adam S Adler; Rena A Mizrahi; Matthew J Spindler; Matthew S Adams; Michael A Asensio; Robert C Edgar; Jackson Leong; Renee Leong; David S Johnson
Journal:  MAbs       Date:  2017-08-28       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.